A greater frequency of cardiac disorders was already reported for RIP and SU, while hypertension was reported for SU and REG, both commonly observed with agents interfering with the vascular-endothelial growth factor (VEGF) pathways and its receptor VEGFR-2 [38,39]. Here, VEGFA is linked to Hypertension.